|
Name |
Hypoxylonol A
|
Molecular Formula | C22H20O5 | |
IUPAC Name* |
(11R,17S,19S)-17-ethoxy-7,15,19-trihydroxypentacyclo[10.7.1.02,11.03,8.016,20]icosa-1,3(8),4,6,12(20),13,15-heptaen-9-one
|
|
SMILES |
CCO[C@H]1C[C@@H](C2=C3[C@H](CC(=O)C4=C3C=CC=C4O)C5=C2C1=C(C=C5)O)O
|
|
InChI |
InChI=1S/C22H20O5/c1-2-27-17-9-16(26)22-18-11-4-3-5-13(23)19(11)15(25)8-12(18)10-6-7-14(24)21(17)20(10)22/h3-7,12,16-17,23-24,26H,2,8-9H2,1H3/t12-,16+,17+/m1/s1
|
|
InChIKey |
DSVFBOXMAJTYHV-DQYPLSBCSA-N
|
|
Synonyms |
Hypoxylonol A; CHEMBL1950966; (1S)-1beta,4,9-Trihydroxy-3alpha-ethoxy-1,2,3,6balpha,7,8-hexahydrobenzo[j]fluoranthene-8-one
|
|
CAS | NA | |
PubChem CID | 57333713 | |
ChEMBL ID | CHEMBL1950966 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 364.4 | ALogp: | 1.9 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 27 | QED Weighted: | 0.741 |
Caco-2 Permeability: | -5.015 | MDCK Permeability: | 0.00001830 |
Pgp-inhibitor: | 0.323 | Pgp-substrate: | 0.998 |
Human Intestinal Absorption (HIA): | 0.304 | 20% Bioavailability (F20%): | 0.967 |
30% Bioavailability (F30%): | 0.993 |
Blood-Brain-Barrier Penetration (BBB): | 0.064 | Plasma Protein Binding (PPB): | 94.99% |
Volume Distribution (VD): | 1.18 | Fu: | 2.38% |
CYP1A2-inhibitor: | 0.133 | CYP1A2-substrate: | 0.862 |
CYP2C19-inhibitor: | 0.236 | CYP2C19-substrate: | 0.57 |
CYP2C9-inhibitor: | 0.716 | CYP2C9-substrate: | 0.968 |
CYP2D6-inhibitor: | 0.275 | CYP2D6-substrate: | 0.246 |
CYP3A4-inhibitor: | 0.294 | CYP3A4-substrate: | 0.478 |
Clearance (CL): | 3.062 | Half-life (T1/2): | 0.059 |
hERG Blockers: | 0.207 | Human Hepatotoxicity (H-HT): | 0.86 |
Drug-inuced Liver Injury (DILI): | 0.759 | AMES Toxicity: | 0.811 |
Rat Oral Acute Toxicity: | 0.9 | Maximum Recommended Daily Dose: | 0.967 |
Skin Sensitization: | 0.649 | Carcinogencity: | 0.103 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.291 |
Respiratory Toxicity: | 0.947 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002855 | 0.863 | D0H6QU | 0.330 | ||||
ENC002856 | 0.780 | D07MGA | 0.305 | ||||
ENC004967 | 0.641 | D0H1AR | 0.290 | ||||
ENC003957 | 0.475 | D01XDL | 0.289 | ||||
ENC003958 | 0.475 | D07VLY | 0.282 | ||||
ENC002122 | 0.475 | D0C9XJ | 0.282 | ||||
ENC003961 | 0.475 | D01XWG | 0.279 | ||||
ENC003960 | 0.460 | D0AZ8C | 0.270 | ||||
ENC000987 | 0.410 | D08NQZ | 0.270 | ||||
ENC005474 | 0.410 | D0S0LZ | 0.270 |